These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21206410)

  • 1. Atomoxetine-induced myocardial infarction.
    Seifi A; Griffith H; Avestimehr S; Dib H
    South Med J; 2011 Feb; 104(2):153-4. PubMed ID: 21206410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy with atomoxetine for US children and adolescents.
    Bhatara VS; Aparasu RR
    Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
    Sert A; Gokcen C; Aypar E; Odabas D
    Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 15. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of severe akathisia with atomoxetine.
    Baweja R; Petrovic-Dovat L
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):426-7. PubMed ID: 23952192
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
    Upadhyaya HP; Desaiah D; Schuh KJ; Bymaster FP; Kallman MJ; Clarke DO; Durell TM; Trzepacz PT; Calligaro DO; Nisenbaum ES; Emmerson PJ; Schuh LM; Bickel WK; Allen AJ
    Psychopharmacology (Berl); 2013 Mar; 226(2):189-200. PubMed ID: 23397050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine-induced mania-like symptoms in an adolescent patient.
    Bahali K; Uneri OS; Ipek H
    Actas Esp Psiquiatr; 2013; 41(2):137-8. PubMed ID: 23592075
    [No Abstract]   [Full Text] [Related]  

  • 19. Atomoxetine-induced hyponatremia.
    Singh T
    Aust N Z J Psychiatry; 2007 May; 41(5):458. PubMed ID: 17464740
    [No Abstract]   [Full Text] [Related]  

  • 20. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.